Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of the American Heart Association
Alessandro Di MinnoMatteo Nicola Dario Di Minno

Abstract

Background Bempedoic acid (BA) is a novel lipid-lowering drug. We performed a systematic review and meta-analysis on efficacy and safety of BA compared with standard treatment in patients with hypercholesterolemia. Methods and Results Studies were systematically searched in the PubMed, Web of Science, Scopus, and EMBASE databases. Efficacy outcome was represented by percentage changes (mean difference [MD] with pertinent 95% CIs) in total cholesterol, low-density lipoprotein cholesterol, triglycerides, high-density lipoprotein cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol, and hs-CRP (high-sensitivity C-reactive protein) in BA patients and controls. Seven studies were included (2767 BA-treated patients and 1469 controls), showing a more significant reduction in low-density lipoprotein cholesterol (MD, -17.5%; 95% CI, -22.9% to -12.0%), total cholesterol (MD, -10.9%; 95% CI, -13.3% to -8.5%), non-high-density lipoprotein cholesterol (MD, -12.3%; 95% CI, -15.3% to -9.20%), apolipoprotein B (MD, -10.6%; 95% CI, -13.2% to -8.02%), and hs-CRP (MD, -13.2%; 95% CI, -16.7% to -9.79%) in BA-treated patients compared with controls. Results were confirmed when separately analyzing studies on patients with high ca...Continue Reading

References

Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Feb 21, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Ronald Goldberg
Dec 3, 2014·Atherosclerosis·Dragana NikolicMaciej Banach
Jun 16, 2015·Journal of Clinical Lipidology·Paul D ThompsonRoger S Newton
May 4, 2016·The American Journal of Cardiology·Christie M BallantyneNarendra D Lalwani
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Sep 28, 2016·JAMA : the Journal of the American Medical Association·Michael G SilvermanMarc S Sabatine
Mar 18, 2017·Journal of the American College of Cardiology·Maria-Corina SerbanRobert S Rosenson
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Aug 22, 2018·Clinical Therapeutics·Jean FerrièresDylan L Steen
Mar 14, 2019·The New England Journal of Medicine·Kausik K RayUNKNOWN CLEAR Harmony Trial
Mar 30, 2019·Journal of the American Heart Association·Ulrich LaufsErik S G Stroes
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Citations

Oct 20, 2020·Expert Review of Clinical Pharmacology·Georgios Polychronopoulos, Konstantinos Tziomalos
Dec 9, 2020·Journal of the American Heart Association·Bimmer E ClaessenRoxana Mehran
Dec 2, 2020·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Ilenia CalcaterraMatteo N D Di Minno
Jul 2, 2021·Expert Opinion on Drug Metabolism & Toxicology·Arrigo F G CiceroIvan Cincione
Jun 17, 2021·Cardiology in Review·William SmithJames Nawarskas

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02993406

Software Mentioned

Cochrane
Comprehensive Meta ‐ Analysis

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

© 2021 Meta ULC. All rights reserved